Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium

Table 4 Results for the two-sample Mendelian randomisation analysis

SNP (Gene)	Effect allele	Phenotype	Association estimates with vasoactive peptides per 1-SD difference		Association estimates with type 2 diabetes		Methods	Mendelian randomisation estimates on odds ratio scale [95% CI]
SNP (Gene)	Effect allele	Phenotype	β (SE)^a	P-value	β (SE)	P-value	Methods
rs5370 (EDN1)	T	CT-proET-1	0.213 (0.020)	1.49E−27	0.024 (0.009)	0.002	Wald ratio	1.12 [1.03; 1.22]; P = 0.011
							Maximum likelihood	1.12 [1.02; 1.22]; P = 0.013
rs2957692 (ADM)	G	MR-proADM	− 0.115 (0.015)	1.05E−12	0.004 (0.016)	0.798	Wald ratio	0.97 [0.74: 1.27]; P = 0.798
							Maximum likelihood	0.96 [0.73; 1.27]; P = 0.798

^aStandardized β estimates
CI confidence interval, CT-proET-1 C-terminal-proendothelin-1, MR-proADM mid-regional-proadrenomedullin, SE standard error, SNP single nucleotide polymorphism

ISSN: 1475-2840